Skip header and navigation

Narrow By

   MORE

2 records – page 1 of 1.

Telemanagement of Inflammatory Bowel Disease

https://libcat.nshealth.ca/en/permalink/provcat39871
Raymond K. Cross, Andrew R. Watson, editors. (1st ed.) --Cham: Springer , c2016.
Available Online
View e-Book
Location
Online
This volume provides a comprehensive, state-of-the art review of inflammatory bowel disease and its management through the use of telemedicine applications. The book reviews barriers to successful outcomes in patients with IBD and offers a rationale for how self-management and telemedicine approaches can improve care in chronic illnesses such as IBD. This volume also includes a summary of the burden of telephone encounters in patients with IBD, characteristics of frequent callers to the office,…
Available Online
View e-Book
Other Authors
Cross, Raymond K
Watson, Andrew R
Responsibility
Raymond K. Cross, Andrew R. Watson, editors
Edition
1st ed.
Place of Publication
Cham
Publisher
Springer
Date of Publication
c2016
Physical Description
1 online resource (xii, 194 p. : 31 illus., 23 illus. in color)
ISBN
9783319222851
9783319222844 (print ed.)
Subjects (MeSH)
Inflammatory Bowel Diseases
Telemedicine - methods
Treatment Outcome
Abstract
This volume provides a comprehensive, state-of-the art review of inflammatory bowel disease and its management through the use of telemedicine applications. The book reviews barriers to successful outcomes in patients with IBD and offers a rationale for how self-management and telemedicine approaches can improve care in chronic illnesses such as IBD. This volume also includes a summary of the burden of telephone encounters in patients with IBD, characteristics of frequent callers to the office, outcomes associated with high telephone use, and strategies to provide education via telephone to patients with IBD. Prior literature on implementation of teleconsultation in research and clinical practice, as well as mobile applications used to track symptoms, quality of life, diet, and medication use in IBD are also explored in the book. Written by experts in the field, Telemanagement of Inflammatory Bowel Disease is a valuable resource for gastroenterologists, surgeons, and other clinicians dealing with, and interested in, this novel adjunct to routine care for inflammatory bowel disease.
Contents
1. Barriers to Successful Outcomes in Patients with Inflammatory Bowel Diseases -- 2. Experience with Telemedicine Systems in Chronic Illness: What Can We Learn -- 3. Telephone Encounters in Inflammatory Bowel Disease (IBD) Care: Burden, Risk Factors, and Opportunities for Intervention -- 4. Teleconsultation in the Care of Patients with IBD -- 5. Self-Management Techniques in IBD -- 6. Mobile Applications for Patients with Inflammatory Bowel Disease -- 7. Telemonitoring and Self-Care in Patients with IBD -- 8. Teleconferences to Facilitate Multidisciplinary Care and Education in IBD -- 9. System Requirements for Delivery of Telemedicine Services -- 10. Legal, Regulatory, and Ethical Issues in the Use of Telemedicine -- 11. Future Directions in Telemedicine Applications for Inflammatory Bowel Disease (IBD).
Format
e-Book
Location
Online
Less detail

Treatment of Inflammatory Bowel Disease with Biologics

https://libcat.nshealth.ca/en/permalink/provcat42935
edited by Adam S. Cheifetz, Joseph D. Feuerstein. --Cham, Switzerland: Springer , c2018.
Available Online
View e-Book
Location
Online
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment …
Available Online
View e-Book
Other Authors
Cheifetz, Adam S.
Feuerstein, Joseph D.
Responsibility
edited by Adam S. Cheifetz, Joseph D. Feuerstein
Place of Publication
Cham, Switzerland
Publisher
Springer
Date of Publication
c2018
Physical Description
1 online resource (xi, 335 p.) : 22 illus., 19 illus. in color
ISBN
9783319602769
9783319602752 (print ed.)
9783319602776 (print ed.)
9783319868233 (print ed.)
Subjects (MeSH)
Anti-Inflammatory Agents - therapeutic use
Biological Products - therapeutic use
Inflammatory Bowel Diseases - drug therapy
Specialty
Biological Therapy
Gastroenterology
Abstract
This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn's disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
Contents
Mechanism of Action and Pharmacokinetics of Biologics -- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis -- Anti-tumor Necrosis Factor Agents in Crohn's Disease -- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease -- Use of Biologics in the Postoperative Management of Crohn's Disease -- Biologics in Pregnancy and Breastfeeding -- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease -- Therapeutic Drug Monitoring of Biologic Agents -- Use of Biologics in Crohn's Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks -- Cessation of Biologics—Can it be Done? -- Biologic Therapy in Pediatric Inflammatory Bowel Disease -- Infectious Complications of Biologics -- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy -- Non-infectious and Non-malignant Complications of Biologics -- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances -- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications -- Novel Agents in Inflammatory Bowel Disease -- Quality, Safety, and Practical Considerations of Using Biologic Therapies.
Format
e-Book
Location
Online
Less detail